OTCMKTS:CHGCYChugai Pharmaceutical Stock Price, Forecast & News

$226.20

+0.23 (+0.10 %)

(As of 04/5/2020 03:50 AM ET)

Add

Compare

Today's Range

$224.03

Now: $226.20▼

$234.49

50-Day Range

$189.64

MA: $211.96▼

$227.70

52-Week Range

$119.92

Now: $226.20▼

$235.00

Volume4,001 shs

Average Volume5,268 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd.; and collaborative research agreement with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Chugai Pharmaceutical.

3.0 Community Rank

Outperform Votes
Chugai Pharmaceutical has received 6 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Chugai Pharmaceutical has received 4 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Chugai Pharmaceutical has received 60.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Chugai Pharmaceutical and other stocks. Vote “Outperform” if you believe CHGCY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHGCY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Chugai Pharmaceutical does not currently pay a dividend.
Dividend Growth
Chugai Pharmaceutical does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.60 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Drug Manufacturers—General

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:CHGCY

Previous Symbol

CUSIPN/A

CIKN/A

Webhttp://www.chugai-pharm.co.jp/

Phone81 3 3281 6611

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees7,432

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

Receive CHGCY News and Ratings via Email

Sign-up to receive the latest news and ratings for CHGCY and its competitors with MarketBeat's FREE daily newsletter.

Chugai Pharmaceutical (OTCMKTS:CHGCY) Frequently Asked Questions

How has Chugai Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Chugai Pharmaceutical's stock was trading at $206.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHGCY stock has increased by 9.6% and is now trading at $226.20. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chugai Pharmaceutical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chugai Pharmaceutical.

Has Chugai Pharmaceutical been receiving favorable news coverage?

News stories about CHGCY stock have trended very negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chugai Pharmaceutical earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutChugai Pharmaceutical.

Who are some of Chugai Pharmaceutical's key competitors?

Some companies that are related to Chugai Pharmaceutical include 1933 Industries (TGIF), 21st North (ULGX), 89bio (ETNB), AAC Technologies (ABSCF), Abacus Health Products (ABAHF), Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acreage (ACRGF), Admedus (AHZ), Advanz Pharma (CXRXF), AEGON (AGN), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY) and AgraFlora Organics International (AGFAF).

Who are Chugai Pharmaceutical's key executives?

Chugai Pharmaceutical's management team includes the following people:

Mr. Osamu Nagayama, Chairman (Age 72)
Mr. Tatsuro Kosaka, Pres, CEO & Representative Director (Age 66)
Mr. Motoo Ueno, Deputy Chairman
Mr. Toshiaki Itagaki, EVP, CFO and GM of Fin. Supervisory Division, Fin. & Accounting Dept.
Mr. Junichi Ebihara, Sr. VP & GM of Legal Department

What is Chugai Pharmaceutical's stock symbol?

Chugai Pharmaceutical trades on the OTCMKTS under the ticker symbol "CHGCY."

How do I buy shares of Chugai Pharmaceutical?

Shares of CHGCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chugai Pharmaceutical's stock price today?

One share of CHGCY stock can currently be purchased for approximately $226.20.

What is Chugai Pharmaceutical's official website?

The official website for Chugai Pharmaceutical is http://www.chugai-pharm.co.jp/.

How can I contact Chugai Pharmaceutical?

The company can be reached via phone at 81 3 3281 6611.

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Featured Article: Certificate of Deposit (CD) For Risk Adverse Investors?